Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.
An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.
Moderna (MRNA) closed the most recent trading day at $193.24, moving +0.09% from the previous trading session.